Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: 2023 drug launch highlights; the M&A outlook for the new year; AstraZeneca’s China cell therapy acquisition; the pre-Christmas deal flow; and India at a turning point for ADCs?
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 5 January 2024, including: 2023 US drug launch highlights; the M&A outlook for the new year; AstraZeneca PLC’s China cell therapy acquisition; the pre-Christmas deal flow; and India at a turning point for ADCs?
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Many Firsts Among The Drugs That Launched In 2023" - Scrip, 1 Jan, 2024.)
(Also see "Going Into 2024, PWC Predicts Healthy Atmosphere For M&A" - Scrip, 3 Jan, 2024.)
(Also see "AstraZeneca's Gracell Acquisition Injects New Excitement For Cell Therapy In China" - Scrip, 2 Jan, 2024.)
(Also see "Stock Watch: The Deal Flow Before Christmas" - Scrip, 2 Jan, 2024.)
(Also see "Late To The Antibody-Drug Conjugate Party, But Will 2024 Be A Turning Point For India?" - Scrip, 4 Jan, 2024.)